GleamWall
中文EN

INMB Inmune Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711754 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY257.1%
TTM net income YoY-9.2%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-48.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-94,766.0%
Net margin-91,866.0%
FCF margin—
EBITDA margin—

Returns

ROE-165.2%
ROA-127.7%
ROIC (approx.)-300.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-64.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$50,000$0
R&D expense——$3.64M$2.33M$4.89M$5.80M$7.64M$7.35M
SG&A expense$1.85M$2.28M$2.17M$3.15M$2.55M$2.25M$2.32M$2.11M
Operating income-$5.01M-$1.48M-$5.81M-$5.47M-$7.43M-$24.57M-$9.90M-$9.47M
Interest expense—————$250,000$0$37,000
Net income-$4.72M-$1.27M-$5.41M-$5.26M-$6.47M-$24.46M-$9.74M-$9.22M
EBITDA-$4.91M-$1.38M-$5.76M-$5.42M————
EPS (basic)-0.17-0.05-0.20—-0.24-1.05-0.43—
EPS (diluted)-0.17-0.05-0.20—-0.24-1.05-0.43—
Weighted avg. shares (diluted)27.81M26.72M26.59M—26.59M23.30M22.50M—
Balance sheet
Cash & equivalents$16.33M$18.41M$21.36M$24.75M$27.73M$33.37M$19.34M$20.92M
Receivables$1.21M$4.41M$479,000$4.28M$1.70M$1.60M$1.28M$1.18M
Current assets$18.71M$23.80M$22.82M$29.89M$30.67M$36.03M$20.96M$22.66M
PP&E, net$1.19M$1.26M$903,000$955,000$878,000$706,000——
Intangibles——————$16.51M$16.51M
Total assets$21.51M$26.84M$25.82M$32.35M$33.36M$37.68M$37.80M$39.56M
Current liabilities$2.92M$5.89M$5.39M$8.42M$7.36M$8.59M$7.93M$7.22M
Long-term debt—————$15.00M$15.00M$15.00M
Total debt—————$15.00M$15.00M$15.00M
Total liabilities$3.44M$6.48M$6.19M$8.83M$7.98M$8.82M$8.13M$7.46M
Shareholders' equity$18.07M$20.36M$19.62M$23.52M$25.38M$28.87M$29.67M$32.10M
Net debt—————-$18.37M-$4.34M-$5.92M
Shares outstanding27.92M27.65M26.59M26.59M26.59M26.59M22.93M22.28M
Cash flow statement
Operating cash flow-$3.39M-$3.17M-$3.40M-$2.94M-$5.44M-$7.38M-$6.82M-$11.01M
Capital expenditure———$143,000$193,000———
Free cash flow———-$3.09M-$5.63M———
Investing cash flow$0——-$143,000-$193,000———
Financing cash flow$1.33M——$67,000$0$22.27M$5.27M-$2.08M
Depreciation & amortization$100,000$100,000$52,000$56,000————
Stock-based compensation$1.12M$1.36M$1.50M$3.32M$2.98M$1.53M$2.08M$1.76M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.